STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells

Prostate

Volumn 42, Issue 3, 2000, Pages 186-195

  Spiotto, Michael T ^a   Chung, Theodore D K ^a,b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Chromogranin A; IL 6; Neuroendocrine; Neuron specific enolase; STAT3

Indexed keywords

CHROMOGRANIN; INTERLEUKIN 6; NEURON SPECIFIC ENOLASE; STAT3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; NERVE FIBER GROWTH; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

CELL DIFFERENTIATION; CELL DIVISION; DNA-BINDING PROTEINS; HUMANS; INTERLEUKIN-6; MALE; PROSTATIC NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034651796     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E     Document Type: Article

References (57)

1. Corti A, Gasparri A, Chen FX, Pelagi M, Brandazza A, Sidoli A, Siccardi AG. Characterization of circulating chromogranin A in human cancer patients. Br J Cancer 1996;73:924-932.
2. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995;144:49-59.
3. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-268.
4. di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-361.
5. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells - a new prognostic parameter in prostate cancer. Br J Urol 1991;68: 258-262.
6. Grignon D, Caplan R, Sakr W, Porter A, Doggen R, John M, Abrams R, Lawton C. Neuroendocrine (NE) differentiation as a prognostic indicator in locally advanced prostate cancer (PCa). Lab Invest 1995;72:76.
7. Weinstein MH, Partin AW, Veltri RW, Epstein IJ. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27: 683-687.
8. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate [Suppl] 1998;8:18-22.
9. Iwamura M, Koshiba K, Cockett AT. Receptors for BPH growth factors are located in some neuroendocrine cells. Prostate [Suppl] 1998;8:14-17.
10. Diaz M, Abdul M, Hoosein N. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate [Suppl] 1998;8:32-36.
11. Qiu Y, Robinson D, Pretlow TG, Kung HJ. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci USA 1998;95:3644-3649.
12. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989;250:607-610.
13. Miles SA, Rezai AR, Salazar-Gonzalez, Vander Meyden M, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T, Martinez-Maza O. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990;87:4068-1072.
14. Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clark SC, Messner HA, Minden MD. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 1989;74:798-804.
15. Revel M. Antitumor potential of interleukin 6. Interferons Cytokines 1991;19:5-8.
16. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-526.
17. Chiu JJ, Sgagias MK, Cowan KH. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 1996;2:215-221.
18. Yamanaka Y, Nakajima K, Fukada T, Hibi M, Hirano T. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J 1996;15:1557-1565.
19. Shimozaki K, Nakajima K, Hirano T, Nagata S. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J Biol Chem 1997;272:25184-25189.
20. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M, Hirano T. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996;15:3651-3658.
21. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141-146.
22. Okamoto M, Webber MM, Quader S, Oyasu R. Interleukin-6 and epidermal growth factor promote anchorage-independent growth of immortalized human prostatic epithelial cells treated with N-methyl-N-nitrosourea. Prostate 1998;35:255-262.
23. Siegall CB, Schwab G, Nordan RP, FitzGerald DJ, Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990;50:7786-7788.
24. Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot P, de Cremoux P, Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996;68:207-214.
25. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998;58:4640-4645.
26. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998;393:83-85.
27. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
28. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996;93:7673-7678.
29. Buard A, Vivo C, Monnet I, Boutin C, Pilatte Y, Jaurand MC. Human malignant mesothelioma cell growth: activation of Janus kinase 2 and signal transducer and activator of transcription 1 alpha for inhibition by interferon-gamma. Cancer Res 1998;58: 840-847.
30. Paonessa G, Graziani R, De Serio A, Savino R, Ciapponi L, Lahm A, Salvati L, Toniatti C, Ciliberto G. Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signaling. EMBO J 1995;14:1942-1951.
31. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, Taga T, Kishimoto T. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993;260:1808-1810.
32. Ward LD, Howlett GJ, Discolo G, Yasukawa K, Hammacher A, Moritz RL, Simpson RJ. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor and gp-130. J Biol Chem 1994; 269:23286-23289.
33. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-98.
34. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle IN, Yancopoulor G. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994;263:92-95.
35. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T, Kishimoto T, Barbieri G, Pellegrini S, Sendtner M, Heinrich PC, Horn F. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994;263:89-92.
36. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994;77:63-71.
37. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, Pellegrini S, Yasukawa K, Heinrich P, Stark GR, Ihle IN, Kerr IM. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J 1995;14:1421-1429.
38. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-1421.
39. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-250.
40. Spiotto MT, Chung TDK. STAT3 mediates IL-6 induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000;42:88-98.
41. Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB, Rosen J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci USA 1995;92:3041-3045.
42. Sadowski HB, Gilman MZ. Cell-free activation of a DNA-binding protein by epidermal growth factor. Nature 1993;362: 79-83.
43. Wu YY, Bradshaw RA. Synergistic induction of neurite outgrowth by nerve growth factor or epidermal growth factor and interleukin-6 in PC12 cells. J Biol Chem 1996;271:13033-13039.
44. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WR, Myers CE, Trepel JB. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994;91:5330-5334.
45. Narimatsu M, Nakajima K, Ichiba M, Hirano T. Association of Stat3-dependent transcriptional activation of p19INK4D with IL-6-induced growth arrest. Biochem Biophys Res Commun 1997;238:764-768.
46. Hauser PJ, Agrawal D, Hackney J, Pledger WJ. STAT3 activation accompanies keratinocyte differentiation. Cell Growth Differ 1998;9:847-855.
47. Ihara S, Nakajima K, Fukada T, Hibi M, Nagata S, Hirano T, Fukui Y. Dual control of neurite outgrowth by STAT3 and MAP kinase in PC12 cells stimulated with interleukin-6. EMBO J 1997; 16:5345-5352.
48. Marz P, Herget T, Lang E, Otten U, Rose-John S. Activation of gp130 by IL-6/soluble IL-6 receptor induces neuronal differentiation [published erratum appears in Eur J Neurosci 1998;10: 1936], Eur J Neurosci 1997;9:2765-2773.
49. Vawter MP, Basaric-Keys J, Li Y, Lester DS, Lebovics RS, Lesch KP, Kulaga H, Freed WJ, Sunderland T, Wolozin B. Human olfactory neuroepithelial cells: tyrosine phosphorylation and process extension are increased by the combination of IL-1beta, IL-6, NGF, and bFGF. Exp Neurol 1996;142:179-194.
50. Dell'Albani P, Kahn MA, Cole R, Condorelli DF, Giuffrida-Stella AM, de Vellis J. Oligodendroglial survival factors, PDGF-AA and CNTF, activate similar JAK/STAT signaling pathways. J Neurosci Res 1998;54:191-205.
51. De-Fraja C, Conti L, Magrassi L, Govoni S, Cattaneo E. Members of the JAK/STAT proteins are expressed and regulated during development in the mammalian forebrain. J Neurosci Res 1998; 54:320-330.
52. Huttner A, Lei T, Fahlbusch R, Schrell W, Adams EF. Relationship between cAMP induced inhibition of human meningioma cell proliferation and autocrine secretion of interleukin-6. Life Sci 1996;58:1323-1329.
53. Ichiba M, Nakajima K, Yamanaka Y, Kiuchi N, Hirano T. Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein. J Biol Chem 1998; 273:6132-6138.
54. Lang D, Miknyoczki SJ, Huang L, Ruggeri BA. Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells. Oncogene 1998;16:1593-1602.
55. Gouyer V, Gazzeri S, Bolon I, Drevet C, Brambilla C, Brambilla E. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors.. Am J Respir Cell Mol Biol 1998;18:188-196.
56. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha, 25-dihyroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 1996;28:182-194.
57. Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993;91:2288-2295.